1800-272-662
Shopping Cart 0
countryflagAU
Login

Alumis Inc

Healthcare US ALMS

26.65USD
-1.45(5.16%)

Last update at 2026-03-11T18:03:00Z

Day Range

26.5828.36
LowHigh

52 Week Range

3.1816.00
LowHigh

Fundamentals

  • Previous Close 28.10
  • Market Cap305.77M
  • Volume520393
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-351.45200M
  • Revenue TTM17.39M
  • Revenue Per Share TTM0.42
  • Gross Profit TTM 17.39M
  • Diluted EPS TTM-10.38

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31
Type yearly yearly
Date 2023-12-31 2022-12-31
Income before tax -154.99300M -111.93000M
Minority interest - -
Net income -154.99300M -111.93000M
Selling general administrative 20.50M 12.55M
Selling and marketing expenses - -
Gross profit -1.28400M -0.25000M
Reconciled depreciation 1.28M 0.25M
Ebit -158.17400M -113.85000M
Ebitda -156.89000M -113.60000M
Depreciation and amortization 1.28M 0.25M
Non operating income net other - -
Operating income -158.17400M -113.85000M
Other operating expenses 158.17M 113.85M
Interest expense - -
Tax provision - -
Interest income 3.37M 1.99M
Net interest income 3.37M 1.99M
Extraordinary items - -
Non recurring - -
Other items - -
Income tax expense - -
Total revenue 0.00000M 0.00000M
Total operating expenses 158.17M 113.60M
Cost of revenue 1.28M 0.25M
Total other income expense net 3.18M 1.92M
Discontinued operations - -
Net income from continuing ops -154.99300M -111.93000M
Net income applicable to common shares - -
Preferred stock and other adjustments - -
Breakdown 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31
Total assets 340.99M 89.61M 108.17M
Intangible assets - - -
Earning assets - - -
Other current assets 16.11M 3.79M 8.98M
Total liab 80.89M 53.50M 17.94M
Total stockholder equity 260.10M 36.11M 90.23M
Deferred long term liab - - -
Other current liab 39.73M 18.03M 10.32M
Common stock 0.00400M 0.00100M 0.00100M
Capital stock 0.00400M 0.00100M 0.00100M
Retained earnings -658.55100M -364.31800M -209.32500M
Other liab - - -
Good will - - -
Other assets - 0.00000M -
Cash 169.53M 46.00M 25.82M
Cash and equivalents - - -
Total current liabilities 50.91M 20.87M 13.35M
Current deferred revenue - -1.11800M -1.72000M
Net debt -138.80400M -13.41600M -24.03700M
Short term debt 1.56M 1.72M 1.31M
Short long term debt - - -
Short long term debt total 30.72M 32.58M 1.78M
Other stockholder equity 918.61M 25.05M 14.21M
Property plant equipment - - -
Total current assets 306.19M 53.36M 102.56M
Long term investments - - -
Net tangible assets - - -
Short term investments 118.74M 2.96M 67.25M
Net receivables 1.81M 0.61M 0.50M
Long term debt - - -
Inventory - - -
Accounts payable 9.62M 1.12M 1.72M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income 0.04M 0.00200M -0.12700M
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other 1.11M 0.00700M 1.14M
Deferred long term asset charges - - -
Non current assets total 34.80M 36.26M 5.61M
Capital lease obligations 30.72M 32.58M 1.78M
Long term debt total - - -
Breakdown 2023-12-31 2022-12-31
Type yearly yearly
Date 2023-12-31 2022-12-31
Investments 60.47M -68.75100M
Change to liabilities - -
Total cashflows from investing activities - -
Net borrowings - -
Total cash from financing activities 89.68M 101.63M
Change to operating activities - -
Net income -154.99300M -111.93000M
Change in cash 20.18M -75.98400M
Begin period cash flow 26.95M 101.80M
End period cash flow 47.13M 25.82M
Total cash from operating activities -129.97500M -107.72200M
Issuance of capital stock 89.78M 99.89M
Depreciation 1.28M 0.25M
Other cashflows from investing activities - -
Dividends paid - -
Change to inventory - -
Change to account receivables - -
Sale purchase of stock -0.06400M -
Other cashflows from financing activities 89.68M 101.63M
Change to netincome - -
Capital expenditures 4.50M 2.41M
Change receivables - -
Cash flows other operating - -
Exchange rate changes - -
Cash and cash equivalents changes - -
Change in working capital 12.06M -1.91600M
Stock based compensation 8.62M 5.96M
Other non cash items 3.05M 6.37M
Free cash flow -134.47400M -110.12800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
ALMS
Alumis Inc		 -1.45 5.16% 26.65 - - 17.58 1.18
NVO
Novo Nordisk A/S		 0.05 0.13% 38.77 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.26 1.45% 491.91 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.47 0.84% 778.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Alumis Inc

280 East Grand Avenue, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Mr. Martin Babler Ph.D. President, CEO & Chairman 1965
Dr. David M. Goldstein Ph.D. Chief Scientific Officer 1966
Mr. Roy C. Hardiman J.D. Chief Business Officer 1960
Mr. John R. Schroer C.F.A. Chief Financial Officer 1965
Ms. Sara Klein Chief Legal Officer & Corporate Secretary 1964
Ms. Claire Langrish Ph.D. Senior VP & Head of Immunology and Translational Science NA
Mr. Philip Nunn Ph.D. Senior VP of Pharmacology & Project Team Leader NA
Dr. Jorn Drappa M.D., Ph.D. Chief Medical Officer 1964
Mr. Mark Bradley Chief Development Officer 1965
Mr. Kolbot By Ph.D. Senior VP & Head of Technical Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.